Studies of perinatal exposures to dioxin-like compounds (DLCs), coplanar polycyclic halogenated aromatics whose prototype is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), have employed a variety of outcome measures to investigate effects on the reproductive/developmental, endocrine, immune, and neurobehavioral systems. The effects include infertility, growth retardation, fetal loss, changed sexual differentiation, reduced cognitive/motor function, dermatologic and other ectodermal effects, and decreased immune response. Significant biomarkers have included sperm count; CD4/CD8 ratio; and levels of testosterone, T4, and dopamine. Using specific dioxin or PCB congeners, these and other markers were used to investigate the mechanisms of the observed effects. The DLCs, which include some PCB congeners, are characterized by high-affinity binding to the Ah receptor; most biological effects are thought to be mediated by the ligand-Ah receptor complex. Other PCB congeners have low affinity for the Ah receptor, and operate by non-Ah receptor mechanisms. The biologic activity of a PCB mixture is the sum of the agonist and antagonist activities of the different constituents in the mixture. Animal studies with specific PCB congeners can help to clarify these activities. With similar approaches, biologic markers of effect can be developed and applied in epidemiologic studies to monitor for, and predict, adverse effects in humans. -Environ Health Perspect 103(Suppl 2): 161-167 (1995) 
Introduction
A biologic marker, or biomarker, is generally defined as any functional or biochemical change in a cell or tissue that is indicative of exposure, response or potential susceptibility to a drug or an environmental agent ( Figure 1 ) (1) . Generally, biomarkers are laboratory-based measures that are intended to increase the sensitivity, specificity, or power of a study to establish a causal association between an exposure and an outcome, and/or provide useful information about the mechanisms involved in exposures, responses, or susceptibilities.
This workshop focused on exposures to a subset of the polycyclic halogenated aromatic hydrocarbons, which include the polychlorinated biphenyls (PCBs), polychlorinated dibenzo-p-dioxins (PCDDs), and polychlorinated dibenzofurans (PCDFs) (Figure 2 ). The latter compounds are by-products of industrial syntheses and chlorine bleaching processes, and can be produced through burning of municipal or industrial waste. Many are persistent environmental contaminants, the most toxic and well studied of which is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The workshop reviewed the evidence that perinatal exposures to these compounds may lead to adverse health outcomes.
Biomarkers of Exposure
Many of the dioxins, dibenzofurans and PCBs resist biodegradation and, because they are lipophilic, concentrate in adipose tissues. Tissue concentrations of these parent compounds serve as good measures of environmental exposures, and residue levels in body fat or in lipid fractions of breast milk or blood are used to quantify this exposure. A vast literature describes the levels of organochlorine residues found in body fluids or tissues of animals and humans, and documents the increased concentration of these contaminants in the fat of animals at successively higher trophic levels of the food chain.
The residue profile (nature and levels of residues) in tissues is unlikely to be identical to the composition of the original envi- genes, and increases the transcription of these genes (11, 12) . The altered transcription of genes in the ligand-Ah-responsive gene battery is believed to be the mechanism by which DLCs produce their biological effects (13) .
Non-DLCs operate by unknown mechanisms. Some non-DLCs are more active in producing certain biologic responses than related DLCs. For example, a noncoplanar PCB congener, PCB 28, is more active in altering dopamine levels in the forebrain of rats than dioxin-like coplanar PCB congeners (14) . This suggests that the neurochemical response is mediated by a non-Ah receptor mechanism, which is consistent with the reported absence of the Ah receptor from neurons (15) .
The discussion below summarizes studies that employ a variety of markers of effect to investigate disease outcomes. Only a few are directly linked to outcome (e.g., sperm count and infertility). Most (24) , and growth retardation in primates and rats (19, 25) . In the endocrine system, the effects included reduced T4 levels in the prefrontal cortex of rats (25) , reduced testosterone levels in rats (22, 23) , and altered dopamine levels in the forebrain of primates and rats (14, 26, 27) . Neurobehavioral effects included spatial learning/memory deficits in primates and rats (27) (28) (29) (30) .
In the immune system, DLCs act as immunosuppressors and immunoenhancers in rats and mice (31) , affecting mainly T-cell responses (31) (32) (33) , although effects on other cells of the immune system are reported (34) (35) (36) . There is suggestive evidence that DLCs affect the primary immune response by changing the CD4/CD8 ratio (the ratio of helper T to suppressor T cells) or the ratio of other lymphocyte subpopulations (31) (32) (33) (37) (38) (39) (40) .
For several of the effects seen in animal studies, there appear to be corresponding outcomes in humans: reductions in infant height and primary immune response in Inuit infants whose mothers had breast milk with high PCB levels (41, 42) ; and reductions in cognitive or motor functions in infants whose mothers ingested PCBcontaminated cooking oil or fish during pregnancy or lactation (16) (17) (18) 43, 44 (14, (25) (26) (27) . Dopaminergic effects were, in addition, age-dependent (26 (34, 47, 48) .
One of the most common observations is for a suppression of the anti-SRBC plaqueforming cell responses in TCDD exposed mice, which may be due to suppression of T-cell responses, although these effects are not observed in rats (31, 49) .
Changes in cell surface markers on Tcells are apparently a particularly sensitive response to the effects of TCDD in nonhuman primates, and have resulted in exploration of this effect as a biomarker in Volume 103, Supplement 2, March 1995 Cell surface markers on T-("thymus") lymphocytes; ratio of "helper" T/"suppressor" T indicates immune function (2 = "normal"; < 1 = compromised). CD29 are "memory" T-cells subset that have been previously activated by antigens; possible marker of sensitivity or effect to DLC exposures. Sheep red blood cell plaque-forming cell assay for ability of B-cells to produce antibody against antigen; most sensitive assay for effects of DLCs in mice. Family of proteins (includes TNF) synthesized in many cells in response to infections, inflammation, and stress; general effectors on metabolism and homeostasis.
Markers for stem cells of lymphocytes in bone marrow; used to demonstrate that DLCs affect development of T-cells. Tumor necrosis factor, produced by macrophages, is an immune system hormone (lymphokine) involved in inflammatory response; in animals, DLCs increase TNF and cause toxic effects (weight loss, death).
humans (39, 50, 51) . DLC exposures change the ratios of lymphocyte subpopulations in rodents and primates (31) (32) (33) (37) (38) (39) (40) , perhaps impairing the primary immune response and accounting for the decreased immunization "take" rates reported for Inuit children (41, 42) . Changes in the ratio of lymphocyte subpopulations (e.g., changed CD4/CD8 ratio) may mean that DLC and/or non-DLC components of PCB mixtures alter the differentiation pattern of cells of the immune system. A mechanism for TCDD-induced thymic atrophy is suggested by a study in mice in which the depletion of bone marrow prolymphocytes (stem cells) following TCDD exposure was measured using markers that are specific for prolymphocytes (terminal deoxynucleotidyl transferase, TdT, and recombinase activating gene, RAG) (32, 33) . In addition to reducing the number of lymphocytes in the thymus gland, TCDD appears to reduce the number of prothymocytes in the bone marrow available to repopulate the depleted thymus. In this way, TCDD's effects on bone marrow are believed to contribute to thymic atrophy.
Neurobehavioral
Perinatal studies with specific PCB congeners and biomarkers suggest a link between behavioral changes in rodents and primates with changes in levels of T4 or dopamine. For example, spatial learning/ memory deficits in monkeys and adult rats are produced by perinatal exposures to specific PCB congeners, especially PCB28 (Schantz), a non-DLC ortho-substituted congener. This same congener also alters dopamine levels in monkeys and rats in specific regions of the brain (26) .
Issues
For perinatal exposures, are there markers of early events that predict later adverse human health outcomes? Can these markers be used to study delayed effects, i.e., predict adverse consequences in newborns and young children, in adults and possibly second generation children? Are these markers linked to exposure? Do they suggest possible public health interventions?
Two examples from the workshop illustrate the difficulties of establishing associations between biomarkers and disease outcomes. Human data suggest that exposure to DLCs changes the ratio of lymphocyte subpopulations (e.g., CD4/CD8 ratio). These changes fall within the range of variation seen in normal, "unexposed" human 
Conclusions
The potential adverse consequences on the reproductive, endocrine, immune, and neurobehaviorial systems of perinatal exposures to dioxins, dibenzofurans, and PCBs are being explored using a variety of biomarkers, including sperm count, CD4/ CD8 ratio, and levels of testosterone, T4, and dopamine. In animal studies, exposures to some of the listed compounds produce changes in the levels of these markers, suggesting that the chemicals affect fertility, impact the endocrine system, cause feminization and demasculinization of males, depress the immune system, and produce neuroendocrine and neurobehavioral effects. These and other markers will be employed in future experimental studies to explore the mechanisms of these effects. If validated, these markers can be used in epidemiologic studies to determine the effects in humans that arise from perinatal exposures to dioxins, dibenzofurans, and PCBs.
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